Please login to the form below

Not currently logged in
Email:
Password:

Opioid analgesic

This page shows the latest Opioid analgesic news and features for those working in and with pharma, biotech and healthcare.

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

Verdict closely follows rejection of Nektar’s opioid analgesic. The FDA’s Anesthetic and Analgesic Committee has rejected yet another opioid drug – this time Intellipharmaceutics’ extended-release oxycodone tablet Aximiris. ... Despite finding

Latest news

  • Nektar’s opioid analgesic slammed with FDA panel rejection Nektar’s opioid analgesic slammed with FDA panel rejection

    High levels of euphoric side-effects from opioid medications have lead to abuse and addiction, which has caused a healthcare crisis to erupt across the US. ... Although the rejection is a blow to Nektar, the opioid painkiller had already been somewhat

  • Insys gets bankruptcy court okay for Subsys sale Insys gets bankruptcy court okay for Subsys sale

    Opioid product was focus of racketeering charges. Insys Therapeutics has been given the green light to sell its Subsys opioid product – the focus of racketeering charges that forced the company to ... Subsys is a sublingual spray formulation of fentanyl

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    Almost forgotten among the interest in Nektar’s immuno-oncology pipeline – which also includes three other candidates in clinical trials – is NKTR-181, a first-in-class, abuse-deterrent opioid analgesic ... The drug promises to deliver pain relief

  • Endo faces industry-first FDA call to pull its opioid painkiller Endo faces industry-first FDA call to pull its opioid painkiller

    The painkiller was first approved in 2006 to manage moderate-to-sever pain when a continuous, around-the-clock opioid analgesic was needed for an extended period of time, but an ... abuse.”. Opioid overdoses killed 33, 000 Americans in 2015 - with half

  • Purdue gets FDA nod for abuse-deterrent painkiller Purdue gets FDA nod for abuse-deterrent painkiller

    Purdue Pharma has expanded its portfolio of opioid analgesic drugs following FDA approval of Hysingla ER, a once-daily product designed to resist abuse. ... The new product will compete in the marketplace against products such as Zogenix' 12-hour Zohydro

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...